Molecular targets in pituitary tumours

被引：80

作者：

Heaney, AP ^{[1
]}

Melmed, S ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Res Inst, Geffen Sch Med, Los Angeles, CA 90048 USA

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 04期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrc1320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pituitary tumours are associated with unrestrained secretion and subsequent action of trophic hormones. One approach to therapy involves suppressing pituitary-hormone hypersecretion without compromising endogenous pituitary function. Identification of novel neuroendocrine-receptor targets has enabled the development of safe and effective receptor ligands that can be used to treat pituitary tumours and associated hormonal excess. Some of these agents, such as somatostatin analogues and a growth-hormone-receptor antagonist, will also have broader applications in treating other cancers and metabolic disorders.

引用

页码：285 / 295

页数：11

共 100 条

[1] CLINICALLY NONFUNCTIONING PITUITARY-TUMORS ARE MONOCLONAL IN ORIGIN [J].

ALEXANDER, JM ;

BILLER, BMK ;

BIKKAL, H ;

ZERVAS, NT ;

ARNOLD, A ;

KLIBANSKI, A .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) :336-340

[2]

[Anonymous], 2003, WILLIAMS TXB ENDOCRI

[3] The pathogenesis of pituitary tumours [J].

Asa, SL ;

Ezzat, S .

NATURE REVIEWS CANCER, 2002, 2 (11) :836-849

[4] Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) [J].

Baldelli, R ;

Colao, A ;

Razzore, P ;

Jaffrain-Rea, ML ;

Marzullo, P ;

Ciccarelli, E ;

Ferretti, E ;

Ferone, D ;

Gaia, D ;

Camanni, F ;

Lombardi, G ;

Tamburrano, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4099-4103

[5] Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment [J].

Ballarè, E ;

Persani, L ;

Lania, AG ;

Filopanti, M ;

Giammona, E ;

Corbetta, S ;

Mantovani, S ;

Arosio, M ;

Beck-Peccoz, P ;

Faglia, G ;

Spada, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3809-3814

[6] Hormonal and metabolic effects of radiotherapy in acromegaly: Long-term results in 128 patients followed in a single center [J].

Barrande, G ;

Pittino-Lungo, M ;

Coste, J ;

Ponvert, D ;

Bertagna, X ;

Luton, JP ;

Bertherat, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3779-3785

[7] GALACTORRHEA - SUCCESSFUL TREATMENT WITH REDUCTION OF PLASMA PROLACTIN LEVELS BY BROM-ERGOCRYPTINE [J].

BESSER, GM ;

MCNEILLY, AS ;

EDWARDS, CRW ;

PARKE, L ;

FORSYTH, IA .

BRITISH MEDICAL JOURNAL, 1972, 3 (5828) :669-&

[8] DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].

BEVAN, JS ;

WEBSTER, J ;

BURKE, CW ;

SCANLON, MF .

ENDOCRINE REVIEWS, 1992, 13 (02) :220-240

[9] CABERGOLINE - AN ADVANCE IN DOPAMINERGIC THERAPY [J].

BEVAN, JS ;

DAVIS, JRE .

CLINICAL ENDOCRINOLOGY, 1994, 41 (06) :709-712

[10]

BONERT VS, 2000, J CLIN ENDOCR METAB, V85, P2958

← 1 2 3 4 5 6 7 8 9 10 →